A detailed history of Fifth Third Bancorp transactions in Corcept Therapeutics Inc stock. As of the latest transaction made, Fifth Third Bancorp holds 487 shares of CORT stock, worth $15,369. This represents 0.0% of its overall portfolio holdings.

Number of Shares
487
Previous 467 4.28%
Holding current value
$15,369
Previous $15,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

BUY
$21.1 - $27.46 $422 - $549
20 Added 4.28%
487 $12,000
Q1 2023

Apr 24, 2023

BUY
$19.2 - $24.47 $2,822 - $3,597
147 Added 45.94%
467 $10,000
Q4 2022

Jan 25, 2023

SELL
$19.95 - $29.96 $957 - $1,438
-48 Reduced 13.04%
320 $0
Q3 2022

Oct 25, 2022

BUY
$24.7 - $29.12 $2,050 - $2,416
83 Added 29.12%
368 $9,000
Q2 2022

Aug 04, 2022

SELL
$17.33 - $25.3 $831 - $1,214
-48 Reduced 14.41%
285 $7,000
Q1 2022

Apr 19, 2022

BUY
$16.53 - $25.21 $3,372 - $5,142
204 Added 158.14%
333 $7,000
Q4 2021

Feb 01, 2022

BUY
$17.1 - $23.34 $478 - $653
28 Added 27.72%
129 $3,000
Q3 2021

Oct 15, 2021

BUY
$19.68 - $22.53 $1,987 - $2,275
101 New
101 $2,000
Q2 2021

Aug 06, 2021

SELL
$19.97 - $24.43 $5,052 - $6,180
-253 Closed
0 $0
Q1 2021

May 07, 2021

BUY
$23.49 - $30.56 $5,942 - $7,731
253 New
253 $6,000
Q1 2019

May 14, 2019

SELL
$10.03 - $15.71 $249,064 - $390,110
-24,832 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$11.29 - $17.19 $187,639 - $285,697
-16,620 Reduced 40.09%
24,832 $332,000
Q3 2018

Nov 14, 2018

BUY
$12.27 - $15.65 $119,031 - $151,820
9,701 Added 30.55%
41,452 $581,000
Q2 2018

Aug 14, 2018

SELL
$15.3 - $19.69 $22,338 - $28,747
-1,460 Reduced 4.4%
31,751 $499,000
Q1 2018

May 15, 2018

BUY
$14.59 - $25.5 $484,548 - $846,880
33,211 New
33,211 $546,000

Others Institutions Holding CORT

About CORCEPT THERAPEUTICS INC


  • Ticker CORT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,105,000
  • Market Cap $3.38B
  • Description
  • Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...
More about CORT
Track This Portfolio

Track Fifth Third Bancorp Portfolio

Follow Fifth Third Bancorp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fifth Third Bancorp, based on Form 13F filings with the SEC.

News

Stay updated on Fifth Third Bancorp with notifications on news.